skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Novel approach to abuse the hyperactive K-Ras pathway for adenoviral gene therapy of colorectal cancer

Journal Article · · Experimental Cell Research
 [1];  [1];  [1];  [2]; ; ;  [1];  [1]
  1. Integrated Cancer Prevention Center, Tel Aviv (Israel)
  2. Lung and Allergy Institute, Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

Background: Functional activation of oncogenic K-Ras signaling pathway plays an important role in the early events of colorectal carcinogenesis (CRC). K-Ras proto-oncogene is involved in 35-40% of CRC cases. Mutations in the Ras gene trigger the transduction of proliferative and anti-apoptotic signals, even in the absence of extra cellular stimuli. The objective of the current study was to use a gene-targeting approach to kill human CRC cells selectively harboring mutated K-Ras. Results: A recombinant adenovirus that carries a lethal gene, PUMA, under the control of a Ras responsive promoter (Ad-Py4-SV40-PUMA) was used selectively to target CRC cells (HCT116, SW480, DLD1 and RIE-Ras) that possess a hyperactive Ras pathway while using HT29 and RIE cells as a control that harbors wild type Ras and exhibit very low Ras activity. Control vector, without the Ras responsive promoter elements was used to assess the specificity of our 'gene therapy' approach. Both adenoviral vectors were assed in vitro and in xenograft model in vivo. Ad-Py4-SV40-PUMA showed high potency to induce {approx} 50% apoptosis in vitro, to abolish completely tumor formation by infecting cells with the Ad-Py4-SV40-PUMA prior xenografting them in nude mice and high ability to suppress by {approx} 35% tumor progression in vivo in already established tumors. Conclusions: Selective targeting of CRC cells with the activated Ras pathway may be a novel and effective therapy in CRC. The high potency of this adenoviral vector may help to overcome an undetectable micro metastasis that is the major hurdle in challenging with CRC.

OSTI ID:
22212292
Journal Information:
Experimental Cell Research, Vol. 318, Issue 2; Other Information: Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0014-4827
Country of Publication:
United States
Language:
English

Similar Records

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer
Journal Article · Fri Jun 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:22212292

Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer
Journal Article · Sat Dec 15 00:00:00 EST 2018 · Experimental Cell Research · OSTI ID:22212292

Adenovirus E2F1 Overexpression Sensitizes LNCaP and PC3 Prostate Tumor Cells to Radiation In Vivo
Journal Article · Tue Feb 01 00:00:00 EST 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22212292